Skip to main content
padlock icon - secure page this page is secure

Nanoformulations of Moxifloxacin, Econozole and Ethionamide as Novel Treatment Regimens Against MDR TB - An Experimental Study

Buy Article:

$68.00 + tax (Refund Policy)

Background: The drugs used for treating multi drug resistant tuberculosis (MDR-TB) are extremely toxic, expensive and less potent with limited sterilizing activity. With the emergence of several drug resistant strains of tuberculosis there is a pressing need for new drug development. In the current study, clinically used anti-infective antibiotics such as moxifloxacin (MOX), econazole (ECZ) and ethionamide (ETH) were encapsulated in poly-(lactide-co-glycolide) nanoaprticles and evaluated for their therapeutic efficacy in a MDR-TB infected mouse model. It is envisaged that such formulations would improve patient compliance and reduction in the number of dosages.

Methods: Moxifloxacin and ethionamide nanoparticles were prepared by multiple emulsion and solvent evaporation method while econazole nanoparticles were prepared by nanopreciptitation method. Mice were aerosol infected with MDR-TB JAL11050 and treated with free drugs and drugs encapsulated in PLGA nanoparticles. The lungs and spleen were evaluated for reduction in bacterial load (colony forming units, CFU) and histopathological studies.

Results: Moxifloxacin, econazole and ethionamide were encapsulated with high efficiency in PLGA nanoparticles. Eight weeks of oral administration of individual nanoformulations (PLGA-NP-ECZ / PLGA-NP-MOX / PLGA-NP-ETH) showed limited reduction of CFUs in lungs and spleen while with 8 doses of a combination of the three nanoformulations (PLGA- NP- ECZ+PLGA-NPMOX+PLGA-NP-ETH) there was a significant reduction in CFUs in lungs as well as in spleen. Corroborating the results with histopathology revealed that the combination of 3-drugs loaded nanoparticles decreased the congestion in the lungs to 50%.

Conclusion: Chemotherapy of MDR-TB infected mice with weekly doses of 3-drugs nanoformulations (PLGA-NPECZ+ PLGA-NP-MOX+PLGA-NP-ETH) led to the clearance of bacilli from lungs and the spleen. This is a first report on the potential efficacy of a combination of ECZ, MOX and ETH nanoparticles against MDR-TB.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Azoles; colony forming units; econazole; ethioanmide; fluoroquinolones; moxifloxacin; multi drug resistant tuberculosis; poly-(lactide-co-glycolide)

Document Type: Research Article

Publication date: February 1, 2016

More about this publication?
  • Current Nanoscience publishes authoritative reviews and original research reports, written by experts in the field on all the most recent advances in nanoscience and nanotechnology. All aspects of the field are represented including nano- structures, synthesis, properties, assembly and devices. Applications of nanoscience in biotechnology, medicine, pharmaceuticals, physics, material science and electronics are also covered. The journal is essential to all involved in nanoscience and its applied areas.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more